Synthesis, crystal structure and antibacterial evaluation of substituted perhydro-1, 3-oxazin-2-ones containing N-phenylsulfonamide

Article abstract of DOI:10.3987/COM-11-12145

The synthesis of a new series of TV-substituted perhydro-1,3-oxazin-2-ones containing V-phenylsulfonamide is described. The compounds 7a-7f were obtained in a one-pot reaction from chlorosulfonyl isocyanate, selected 1, 3-halogenoalcohols and various aromatic amines in alkaline conditions, to give the target N-heterocyclic 6-membered ring compounds with good yields. The X-ray crystal structure of N-[(N-4-fluorophenyl)sulfamoyl]perhydro-1, 3-oxazin-2-one 7d was solved. All the synthesized compounds have been screened for their invitro antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Structures of 7d and 6e can be further optimized to give new potent antibacterial agents with structures significantly different from those of existing classes of antibiotics. The Japan Institute of Heterocyclic Chemistry.

Full text of DOI:10.3987/COM-11-12145

HETEROCYCLES, Vol. 83, No. 5, 2011
1041
HETEROCYCLES, Vol. 83, No. 5, 2011, pp. 1041 - 1056. © The Japan Institute of Heterocyclic Chemistry
Received, 21st January, 2011, Accepted, 3rd March, 2011, Published online, 10th March, 2011
DOI: 10.3987/COM-11-12145
SYNTHESIS, CRYSTAL STRUCTURE AND ANTIBACTERIAL
EVALUATION OF N-SUBSTITUTED PERHYDRO-1,3-OXAZIN-2-ONES
CONTAINING N-PHENYLSULFONAMIDE
Mounir Nessaib,1 Abdelghani Djahoudi,2 Achour Seridi,1,3 Hocine Akkari,3
Nour-Eddine Aouf,4 Jean-Claude Daran,5 and Mohamed Abdaoui1*
1Laboratory of Applied Chemistry. University of May 8th, 1945. BP 401, Guelma,
Algeria
2Laboratory of Microbiology, Faculty of Medicine, University of Badji Mokhtar,
BP 205, Annaba, Algeria
3Department of Fundamental Sciences, University of August 20th, 1955. BP 26,
Skikda, Algeria
4Laboratory of organic applied chemistry, University of Badji Mokhtar. BP 12,
Annaba, Algeria
5Laboratory of Coordination chemistry, UPR 8241, 205, 31077 Toulouse, France
Corresponding Author’s: Professor Mohamed Abdaoui and Dr. Hocine Akkari
E-mail: abdaoui.mohamed@univ-guelma.dz and hocine_akkari@yahoo.fr
Abstract - The synthesis of a new series of N-substituted perhydro-1,3-oxazin-2-
ones containing N-phenylsulfonamide is described. The compounds 7a–7f were
obtained in a one-pot reaction from chlorosulfonyl isocyanate, selected 1,3-
halogenoalcohols and various aromatic amines in alkaline conditions, to give the
target N-heterocyclic 6-membered ring compounds with good yields. The X-ray
crystal structure of N-[(N-4-fluorophenyl)sulfamoyl]perhydro-1,3-oxazin-2-one
7d was solved. All the synthesized compounds have been screened for their in-
vitro antibacterial activity against Staphylococcus aureus, Escherichia coli and
Pseudomonas aeruginosa. Structures of 7d and 6e can be further optimized to
give new potent antibacterial agents with structures significantly different from
those of existing classes of antibiotics.

1042
HETEROCYCLES, Vol. 83, No. 5, 2011
1. INTRODUCTION
The emergence of bacterial resistance to the antibiotics has posed a serious concern for medical
professionals during the last decade.1 In particular, multi-drug-resistant Gram-positive bacteria, including
methicillin-resistant Staphylococcus aureus (MRSA),2 Staphylococcus epidermidis (MRSE) and
vancomycin-resistant Enterococci (VRE) are of major concern.3 These bacteria are very dangerous and
can be life-threatening especially for patients whose immune systems have been compromised due to HIV,
surgery or any other diseases. Oxazolidinones and sulfonamides represent two classes of medicinally
important compounds which are extensively used as antibacterial agents. Oxazolidinones are the only
new class of synthetic antibacterial agents over the past 30 years that possess totally new structures
compared to existing antibacterial agents.4–7 It is well known that oxazolidinones bind to the 50S subunit
of the bacterial ribosome and inhibit protein synthesis at a very early stage by preventing the initiation of
mRNA translation. Because they target the bacterial protein synthesis at an early stage, drug resistance
was expected to be rare. However, resistance to linezolid (Zyvox®) has already been reported.8,9 For the
sulfonamides -often called simply sulfa drugs-, it is well documented that this class of compounds
interferes with PABA (p-aminobenzoic acid) in the biosynthesis of tetrahydrofolic acid10 which is a basic
growth factor that is essential for the metabolic process of bacteria. Many activities apart from carbonic
anhydrase have been reviewed as anti-inflammatory, tubular transport inhibition and insulin release.11
In our days many new antibacterial agents are designed based on modification of the existing structural
classes, since the antibiotic assay is easy to be carried out. The action modes of the agents are often
discovered after finding them active. Identifying fragments features in existing drug classes and
incorporating them into a de novo design of a new compound is an efficient recent method to discover
new drugs with significantly different structure motifs.12 For example, in some structures of recent
biologically active small compounds shown in Figure 1 which include; linezolid 1,1,3-oxazinan-2-one 2,
Benzensulfonanilide, 3 indeglitazar (PAPAR) 4 and 4-azidomethyl-7-methylcoumarin-6-sulfonamide 5.
We can observe that the common general features of these agents are that they all contain phenyl
sulfonamide and/or heterocyclic structures, and they have heteroatom substituent such as halo, amino and
methoxy groups. Linezolid 1 has the oxazolidinone as the core structure, which is important for its
activity. Bulk of literature reveals that several compounds containing N-heterocyclic 6-membered ring as
1,3-oxazinan-2-one 2 derivatives form compounds of pharmacological interest such as antibacterial
activities,13 anti-inflammatory14 and anti-thrombotic.15 Benzensulfonanilide 3 is a recent example of anti-
MRSA/VRE type compounds containing phenylsulfonyl group.16 Indeglitazar (PAPAR) 4 recently cited
by Artis et al,17 is expected to be useful in the treatment of Type 2 diabetes mellitus. Indeglitazar has
now progressed to Phase II clinical evaluations. 4-azidomethyl-7-methylcoumarin-6-sulfonamide 5 is a
novel sulfonamide containing 4-azidomethylcoumarin with a potent antibacterial activity.18

HETEROCYCLES, Vol. 83, No. 5, 2011
1043
CF3
O
O
F
O
O
N
O
HN
S
Cl
R'
H
O
N
N
N
H
CF3
O
NH2
O
2
1
3
Cl
O
S
O
O
R'
H
O
O
O
Me
O
MeO
OMe
O
N
O
Me
OMe
Br
Cl
NO2
N
HO
S
S
N
N
O
N3
O
H
5
H or Me
MeO
4 (Indeglitazar)
6
Figure 1. Some Structures of Recent Biologically Active Small Compounds
The general features of these compounds can be used to design new structures that can be potentially
useful as antibacterial agents. For this purpose, at present, many efforts are focused on substituted
phenyloxazolidinones and/or phenylsulfonamide. Previously,19 we described the synthesis and
antibacterial activity of some N-[(N-aryl)sulfamoyl]oxazolidin-2-ones 6 (Figure1) derivatives against only
Staphylococcus aureus strain; Based on the positive effect of sulfonamide moieties on the activity of
oxazolidinones, especially against both Gram-positive and Gram-negative bacteria.20-22 In addition, Wang
et al13 described that synthesized compounds having 6-membered ring 1,3-oxazinan-2-one instead of 5-
membered ring oxazolidinones have slightly more potent antibacterial activity. Considering this
background, the objective of this study is to obtain more potent antibacterial compounds, by combining
the chemistry of sulfonamide with perhydro-1,3-oxazin-2-one. A new class of N-[(N-aryl)sulfamoyl]-
perhydro-1,3-oxazin-2-ones 7 (n=2) (Scheme 1) is reported in this paper. To our knowledge, antibacterial
activity of these compounds and their analogs has not been investigated. Their use is limited to the
preparation of various 2-chloroethylsulfamides,23,24 transfamoylation reaction,25 or as ligands in inclusion
complex by β-cyclodextrin.26
In this work, we present the synthesis, characterization, crystal structure and antibacterial activity
evaluation of some N-[(N-aryl)sulfamoyl]perhydro-1,3-oxazin-2-ones isomers 7a-7f (Scheme 1) obtained
in one-pot reaction starting from chlorosulfonylisocyanate (CSI) 8 (Scheme 1), selected 1,3-
halogenopropanol (n=2) and various aromatic amines in alkaline conditions, to give the synthesis of the
target N-heterocyclic 6-membered ring in good yields. Several of these molecules exhibit potent
antibacterial activities against tested Staphylococcus aureus, E.coli and Pseudomonas aeruginosa clinical
strains.

1044
HETEROCYCLES, Vol. 83, No. 5, 2011
2. RESULTS AND DISCUSSION
2.1 CHEMISTRY
The Preparation of N-[(N-aryl)sulfamoyl]perhydro-1,3-oxazin-2-ones 7a-7f was carried out starting from
chlorosulfonylisocyanate (CSI) 8, 1-3 halogenoalcohols (n=2), aromatic amines and triethylamine (TEA)
through a previously described one-pot procedure.23 The isolation of the linear sulfamoylcarbamates 9 is
not the aim of this study and it reduces the total yield. The used halogenoalcohols was 3-bromo-1-
propanol or 3-chloro-1-propanol (Scheme 1).
7
6
( n =1) [19]
6a (60%)
6b (85%)
O
R
(n =2)
TEA
O
S
7a (65%)
7b (64%)
7c (67%)
7d
7e (65%)
7f (69%)
H
Ph
O C N S Cl
H
N
O
S
-HX
H
p
-MePh
N
O
X
1.
O
p
p
p
p
N
N
6c 68%)
X
-MeOPh
-FPh
-ClPh
(
n
R
OH
CSI
n
O
n
(X=Cl ,Br)
O
6d
(68%)
(66%)
O
O
9
R
6e (71%)
6f (79%)
RNH
2.
2
O
8
-NO2Ph
Scheme 1. Preparation of perhydro-1,3-oxazin-2-ones derivatives 7a-7f
Insitu cyclization is observed for the linear N-sulfamoylcarbamate 9 (n=2) which is achieved by
triethylamine (TEA) addition, to give perhydrooxazinones 7. This intramolecular cyclization was reported
by Dewynter et al,23 These compounds were formed by spontaneous cyclization during the first step
related to the excellent leaving group character of Cl and Br. No cyclization is observed related to the
sulfamide moiety. This is probably in relation with the rotational barrier level around the sulfamido
group.27,28 Some physical and spectral data of the synthesized compounds 7a-7f were summarized in
section 4. All of the perhydrooxazinones isomers 7 are crystalline and thermally stable compounds. The
structural study was completed by crystallographic analysis.
2.2 X-RAY ANALYSIS OF COMPOUND 7d
Apart from the fluoro derivative of N-[(N-aryl)sulfamoyl]perhydro-1,3-oxazin-2-one, the other isomers
were not well crystallized to be suitable for X-ray diffraction in spite of several attempts of
recrystallization. In view of that, a colorless prism-shaped crystal of 7d, 0.2 × 0.1 × 0.1, were carefully
selected under a polarizing microscope and glued at the tip of a thin glass fiber. Data collection was
carried out using Oxford Diffraction Xcalibur CCD diffractometer equipped with sealed tube X-ray
source (Mo-Kα radiation, λ = 0.71073 Å). All calculations, i.e., data collection, cell refinement and data
reduction were performed using CrysAlis CCD and CrysAlis RED.29 Significant details of the data
collection and crystal data for 7d are presented in Table 1.

HETEROCYCLES, Vol. 83, No. 5, 2011
1045
Table 1. Experimental crystallographic parameters for 7d
Crystal data
Empirical formula
C10 H11 F N2 O4 S
274.27
Formula weight
System
monoclinic
P21/c (14)
7.815(5)
Space group
a (Å)
b (Å)
13.072(5)
12.094(5)
106.077(5)
1187.2(10)
4, 1.535
c (Å)
β (°)
V (Å3)
Z, Calculated density (g.cm-3)
Crystal habit, colour
Crystal size (mm)
Absorption coefficient (mm-1)
F(000)
Prism, colourless
0.2 × 0.1 × 0.1
0.295
568
Data collection
Temperature (K)
Diffractometer
293
Xcalibur Oxford diffraction
0.71073
Wavelength Mo(Kα) (Å)
θ range (°)
3.12 - 30.02
Limiting indices
-11≤ h ≤ 10, -15 ≤ k ≤ 18, -16 ≤ l≤ 17
Reflections collected/unique
10938 / 3462 [R(int) = 0.0206]
Structure refinement
Refinement method
Full-matrix least-squares on |F2|
3462/1/166
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
1.079
R1 = 0.0455, wR2 = 0.1096
R1 = 0.0598, wR2 = 0.1187
0.379 and -0.368
Largest difference peak and
Hole (e Å-3)
The structure was solved by direct methods and refined by full-matrix least-squares techniques using the
SIR-9730 and SHELXL-9731 programs respectively. Sulfur, nitrogen, oxygen and carbon atoms were
located on the basis of 2787 independent reflections and anisotropically refined. All H atoms attached to

1046
HETEROCYCLES, Vol. 83, No. 5, 2011
C atoms were fixed geometrically and treated as riding with C---H = 0.97 Å (methylene) and 0.89 Å
(phenyl) with Uiso(H) = 1.2Ueq(C) times Ueq(C). The coordinates of the H atom attached to N2 were
refined using N-H restraint [0.86(1) Å] and with Uiso(H) = 1.2 times Ueq(N). Pertinent details of the data
collection and crystal data for 7d are presented in Table 1. Selected bond lengths and angles are given in
Table 2.
Table 2. Selected bond lengths (A°) and angles (°) with their standard deviations relevant to 7d
Bond lengths (A°)
Bond angles (°)
O11 − S1 − O12
N1 − S1 − N2
1.414(2)
120.46(10)
106.25(8)
103.04(9)
109.33(9)
109.58(9)
107.35(9)
S1 − O11
S1 − O12
S1 − N1
S1 − N2
N1 − C11
N1−C14
N2−C21
C24−F1
1.417(2)
1.681(2)
1.613(2)
1.371(2)
1.485(2)
1.435(2)
1.354(2)
O11 − S1 − N1
O11 − S1 − N2
O12 − S1 − N1
O12 − S1 − N2
2.3 CRYSTAL STRUCTURE STUDY
The structure of 7d is shown in Figure 2. From Table 1, it is clear that the molecular geometry of 7d is in
good agreement with related structure.33,34 Accordingly, the asymmetry of S-N bond lengths is shown
within the sulfamid moiety N1-S1-N2, with values of 1.681(2) A° for the first bond and 1.613(2) Å for
the second.
Figure 2. ORTEP32 plot of the molecule 7d in the crystal with atomic numbering scheme. Ellipsoids
correspond to 50% probability levels and H atoms are shown as small spheres of arbitrary radii.

HETEROCYCLES, Vol. 83, No. 5, 2011
1047
The interesting feature in the crystal packing is that the arrangement of the molecules gives rise to a
pseudo dimer through N-H…O hydrogen bonds building a R22 (12) ring according to the graph set
theory35,36 as shown in Figure 3. Several weak intermolecular interactions participate in the molecular
interconnection.
These interactions are set up via C–H···O sulfonamide (O11 and O12) and carbonyl (O2) functions in
addition to C–H···F intermolecular interaction via halogen function as shown in Table 3. All these
interactions lead to an infinite three-dimensional network.
Figure 3. DIAMOND37 plot of a 10-member hydrogen-bonded head-to-head cyclic dimer [R22 (12)]
involving N-H…O intermolecular interaction. Hydrogen bonds are shown as blue dashed lines.
Table 3. Strongest hydrogen bonds and interactions for 7d
D−H⋅⋅⋅Aa
d(H⋅⋅⋅A) (Å) d(D⋅⋅⋅A)
d DH⋅⋅⋅A (°)(Å)
d(DH) (Å)
N2 − H2⋅⋅⋅O2I
0.854(18)
0.97
2.04(2)
2.42
2.863(3)
3.234(3)
3.283(3)
3.234(3)
3.282(3)
162(2)
141
C12 − H12A⋅⋅⋅F1II
C12 − H12B⋅⋅⋅O2III
C14 − H14B⋅⋅⋅O12IV
C23 − H23⋅⋅⋅O11V
0.97
2.46
143
0.97
2.44
138
0.93
2.42
154
aSymmetry code : (I) -x+2, -y, -z; (II) -x+2, -y, -z+1; (III) -x+1, -y, -z; (IV) x, -y-1/2, z-1/2; (V) -x+2, -y+1/2, -z+1/2
2.4. IN-VITRO ANTIMICROBIAL TESTS (FIRST SCREENING)
.
All compounds 7a-7f were tested against one Gram-positive (S. aureus) and two Gram-negative (E. coli
and Pseudomonas aeruginosa) clinical strains, isolated from patients with various (cutaneous, urinary,
and pulmonary) infections at Annaba University Hospital. Using the disc diffusion method as described
in Section 4.4, all the synthesized compounds exhibited varying degree of inhibitory effect on the growth

1048
HETEROCYCLES, Vol. 83, No. 5, 2011
of different tested strains (Table 4). A significant activity was observed for the compound 7d against S.
aureus. Compounds 7a and 7b showed moderate activity. Whereas, compounds 7a, 7c, 7d showed
moderate activity against E. Coli. For P. aeruginosa, Compounds 7c and 7d showed moderate activity,
whereas compounds 7e, 7f showed weak activity against all Gram-negative and positive-gram bacterial
strains.
Table 4. Antibacterial Bioassay (used 300 μ mol/L in DMSOa) of 7a-7f
Inhibitory zoneb (mm) at 300 μ mol/L
Compounds
R1
S. aureus
13,1
10,2
8,1
21,1
6
E. coli
10,2
6,4
12,1
11,1
8,1
P. aeruginosa
8,1
6
7a
7b
7c
7d
7e
Ph
p-Me Ph
p-MeO Ph
p-FPh
p-ClPh
p-NO2Ph
-
10
14,1
8,3
6,5
24
7f
7,4
26
7,9
20
SDC
aAntibacterial Activity was determined by disc diffusion method as described in Section 4.4
b[zone of inhibition (mm) by disc diffusion method]:<10: weak; >10: moderate; >16: Significant.
CStandard drug (Sulfisoxazole)
Although, for structure comparison purposes, we have also resynthesized and tested 6a-6f analogs19 (n=1,
shown in Scheme 1) for their antibacterial activity against the same test strains. These compounds contain
an oxazolidin-2-one ring instead of a perhydro-1,3-oxazinan-2-one ring. The biological assay data in
Table 5 showed that compounds 6e, 6a and 6b have a significant activity against P. aeruginosa strain of
bacteria. Whereas, compound 6d showed moderate activity against all Gram-negative and Gram-positive
bacterial strains. All other compounds showed weak activity against all other tested strains.
Table 5. Antibacterial Bioassay (used 300 μ mol/L in DMSOa) of 6a-6f
Inhibitory zoneb (mm) at 300 μ mol/L
Compounds
R1
S. aureus
E. coli
P. aeruginosa
6a
6b
6c
Ph
8,7
9,1
19,2
17,4
6
p-Me Ph
p-MeO Ph
p-FPh
8,3
7,6
8,8
7,1
6d
6e
10,3
8,2
11,2
8,5
11,1
26,2
6
p-ClPh
p-NO2Ph
-
6f
SDC
9,1
7,9
26
20
24
aAntibacterial Activity was determined by disc diffusion Method as described in section 4.4
b[zone of inhibition (mm) by disc diffusion method]<10: weak; >10: moderate; >16: Significant.
CStandard drug (Sulfisoxazole)

HETEROCYCLES, Vol. 83, No. 5, 2011
1049
Relying on these results, we propose that active compounds exhibit certain potent strain-specificity. From
the literature, it is common for some bacteria strains to be resistant and others is susceptible to a particular
antibiotic.38,39 The comparison of Inhibition results of synthesized compounds 6a-6f and 7a-7f (Figure 4)
showed that the compound 7d was found to be the most active against Gram-positive (S. aureus), and the
compound 6e was the most active against Gram-negative (P. aeruginosa). But for E. coli, all compounds
showed weak and/or moderate activity. The preliminary structure–activity relationship (SAR) of
compounds containing perhydro 1,3-oxazin-2-one ring showed that the nature of substituent in para
positions of the phenyl ring affected the activity significantly. A general trend is that non-polar groups are
more favorable than polar groups on the benzyl ring. Possessing H, Methoxy (-OMe) and halogen groups
(F and Cl) substituent, frequently appear in many antibacterial drug structures, exhibited potent
antibacterial activity against all tested strains. Introducing the polar nitro group on para position reduces
this activity.40 Basing on the crystal structure study, this observation may be attributed to the electron-
withdrawing (EW) character of the para-substituents.25
Figure 4. Antibacterial activity comparison of synthesized compounds 6a-6f and 7a-7f
Although, In Figure 4, we can observe that the 6-membered ring perhydro-1,3-oxazinan-2-one is slightly
more potent than the 5-membered ring oxazolidin-2-ones against Gram-positive (S. aureus) and Gram-
negative (E. coli).13 But for 6a, 6b and 6e with H, p-Me, p-Cl respectively substituents on the phenyl ring,
oxazolidin-2-ones compounds still showed a good activity against Gram-negative (P. aeruginosa).

1050
HETEROCYCLES, Vol. 83, No. 5, 2011
2.5. MINIMUM INHIBITORY CONCENTRATION (MIC) FOR ANTIBACTERIAL ACTIVITY
The data obtained after preliminary antibacterial screening showed that compounds 7d, 6a, 6b and 6e
were the most active, their inhibitory zone values were 21.1, 19.2, 17.4 and 26.2 (>16 mm) respectively.
These compounds were therefore, selected for antibacterial minimum inhibitory concentration (MIC)
studies (Table 6).
Table 6. MIC (µg/mL) of the selected compounds (7d), (6a), (6b) and (6e) against selected bacteria
Gram-positive
Gram-negative
Compounds
S. aureus
E. coli
P. aeruginosa
7d
6a
6b
6e
2
8
16
≥ 250
16
(-)
(-)
( -)
(-)
(-)
(-)
8
SD*
8
>125
62,5
* Standard drug (Sulfisoxazole)
(-) No tested
The biological assay data in Table 6 showed that the MIC of these most active compounds was in the
range of 7,292 x10-6 M to 1,031 x10-3 M. The Compound 7d proved to be the most active one against
Gram-positive and Gram-negative isolated clinical strains; It inhibited the growth of S. aureus at 2
µg/mL (7,292 x10-6 M) and E. coli at 8 µg/mL (2,916 x10-5 M) while compound 6e proved to be the
most active one against Gram-negative strain; It inhibited the growth of P. aeruginosa at 8 µg/mL (2,891
x10-5 M). These are good activities, considering the simplicity of the structure and the differences with
Sulfisoxazole or other existing antibacterial agents.
It is well known that sulfa drugs act as dihydropteroate synthase (DHPS) inhibitiors in the synthetic
pathway of folate, thereby causing DNA and RNA synthesis inhibition.41,42 But all of these compounds
do not possess an amino group on the benzene moiety. Though, an amino group is essential for
Dihydropteroate synthase (DHPS) inhibition. With these Preliminary results we suggest that the
mechanism of the antibacterial action of 7d and 6e is different from that of sulfa drugs.
3. CONCLUSIONS
The results of the present investigation support the suggested structures of N-substituted perhydro-1, 3-
oxazin-2-ones containing N-phenylsulfonamide and their analogs oxazolidin-2-ones. It has been

HETEROCYCLES, Vol. 83, No. 5, 2011
1051
suggested that some functional groups such as methoxy (-OMe) or halo-atoms (F, Cl) substituents on the
benzene ring present in these compounds, play a chief role in biological activity.13,16-18 The potent
antibacterial properties of synthesized compounds encouraging us for purposes of new drug design
suggesting that very likely most of these compounds could be used as potential antibacterial activity after
minor modifications. From these results, several pertinent observations are revealed: (i) inhibition effect
of tested compounds depends on substituent nature in para position on the benzene ring, (ii) H, fluoro,
chloro, and methoxy are good substituents, (iii) The 6-membered ring 1,3-oxazin-2-one seems to have a
slightly better activity than the oxazolidin-2-ones. Moreover, experimental data show that the compound
7d and 6e may also be used to further optimization of structures to obtain potent novel antibacterial drugs
against Gram-positive (S. aureus) and Gram-negative (E. coli, P. aeruginosa) strains.
4. EXPERIMENTAL
4.1. General
Starting materials were obtained from commercial suppliers and were used without further purification.
Before use, aniline was purified by distillation over NaOH under reduced pressure. The substituted
anilines were used without further purification. Melting points were determined with a Electrothermal
melting point apparatus (IA9000). IR spectra were recorded on Perkin Elmer FT-IR 1725 (KBr). 1H NMR
spectra were recorded on a Brüker Avance (300 MHz) spectrometer using DMSO-d6 or CDCl3 as solvent.
Proton chemical shifts were referenced to the TMS internal standard. Electrospray Ionization mass
spectra (ESI-MS) (30eV and 20eV) were recorded in positive mode on a Water MicroMass ZQ. Thin
layer chromatography (TLC) analysis was performed on silica gel/TLC-cards (Fluka). Spots were
visualized under 254 nm UV illuminations by ninhydrin solution spraying. Chromatography columns
were carried out using Silica Gel Merck 60. X-Ray crystal diffraction data was cited in Section 2.2.
4.2 Typical Operating Procedure for Synthesis of N-[(N-Aryl)sulfamoyl]perhydro-1,3-oxazin-2-ones
7a-7f : To a solution of chlorosulfonyl isocyanate (CSI) (4.5g, 31.8 mmol) in CH2Cl2 (40 mL ) at room
temperature and under a nitrogen atmosphere. The reaction mixture was cooled to about 1 °C, and a
solution of halogeno-alcohol (4.00 g, 32 mmol, 1,1 equiv) in dried CH2Cl2 (10 mL) was slowly added
over 5 min. at 0 °C. Stirring of the reaction mixture was continued at the same temperature for a
minimum of 20 min. This reagent of carbamoylation reaction and 2.2 equiv of triethylamine (TEA) was
slowly added (dropwise) at 0 °C into a solution containing the primary amine (aniline or para-substituted
anilines) (0.05 mol 1.1 equiv in 100 mL of CH2Cl2). Progress of this reaction was monitored by TLC. The
reaction was achieved in 45 min. The medium was diluted with CH2Cl2 (100 mL), washed with two
fractions of HCI 0.1 N. Then the decanted and separated organic layer was washed with water, dried and
concentrated. The crude residue of N-[(N-aryl)sulfamoyl]perhydro-1,3-oxazin-2-ones was then purified

1052
HETEROCYCLES, Vol. 83, No. 5, 2011
by column chromatography (yields 64-69%).
4.2.1. N-[(N-Phenyl)sulfamoyl]perhydro-1,3-oxazin-2-one (7a). According to the typical operating
procedure (4.2) using the 1,3 chloropropanol as halogeno-alcohol, 7a was obtained in 65.02% yield as
white solid after column chromatography (eluent: CH2Cl2/MeOH = 95:5) and recrystallization from
CH2Cl2/n-hexane. Mp 163-165 °C; Rf: 0.65 (CH2Cl2/MeOH = 95:5); IR (KBr, cm-1): 3219 (NH), 1697
(C=O), 1271, 1190 (SO2); 1H NMR (300 MHz, CDCl3) 1.89 (q, 2H), 3.59 (t, J = 6.26 Hz, 2H), 4.22 (t, J
= 5.17 Hz, 2H), 7.26-7.31 (m, 3H), 7.35-7.38 (m, 2H), 7.6 (br s, 1H), [M+Na+] = 279.05.
4.2.2. N-[(N-P-Toloyl)sulfamoyl]perhydro-1,3-oxazin-2-one 7b. According to the typical operating
procedure (4.2) using the 1,3-chloropropanol as halogeno-alcohol, 7b was obtained in 64.69% yield as
colorless solid after column chromatography (eluent: CH2Cl2/MeOH = 95:5) and recrystallization from
CH2Cl2/n-Hexane. Mp 177-179 °C; Rf: 0.63 (CH2Cl2/MeOH = 95:5); IR (KBr, cm-1): 3212 (NH), 1702
1
(C=O), 1273, 1163 (SO2); H NMR (300 MHz, CDCl3) 1.90 (q, 2H), 2.36 (s, 3H), 3.57 (t, J = 6.18 Hz,
2H), 4.23 (t, J = 5.36 Hz, 2H), 7.17-7.28 (m, 4H), 7.47 (br s, 1H), [M+Na+] = 293.06.
4.2.3. N-[(N-4-Methoxyphenyl)sulfamoyl]perhydro-1,3-oxazin-2-one 7c. According to the typical
operating procedure (4.2) using the 1,3-chloropropanol as halogeno-alcohol, 7c was obtained in 67.99 %
yield as gray solid after column chromatography (eluent: CH2Cl2/MeOH = 95:5) and recrystallization
from CH2Cl2/n-hexane. Mp 183-185 °C; Rf: 0.55 (CH2Cl2/MeOH = 95:5); IR (KBr, cm-1): 3201 (NH),
1669 (C=O) 1269, 1155 (SO2); 1H NMR (300 MHz, CDCl3) 1.91 (q, 2H), 3.54 (t, J = 6.21 Hz, 2H), 3.82
(s, 3H), 4.24 (t, J = 5.32 Hz, 2H), 6.88-6.91 (dm, 2H), 7.21-7.28 (dm, 2H), 7.41 (br s, 1H), [M+Na+] =
309.06.
4.2.4. N-[(N-4-Fluorophenyl)sulfamoyl]perhydro-1,3-oxazin-2-one 7d. According to the typical
Operating Procedure (4.2) using the 1,3-chloropropanol as halogeno-alcohol, 7d was obtained in 66.63%
yield as colorless solid after column chromatography (eluent: CH2Cl2/MeOH = 95:5) and recrystallization
from CH2Cl2/n-hexane. Mp 190-192 °C; Rf: 0.62 (CH2Cl2/MeOH = 95:5); IR (KBr, cm-1): 3292 (NH),
1703 (C=O) 1273, 1163 (SO2); 1H NMR (300 MHz, CDCl3) 1.93 (q, 2H), 3.58 (t, J = 6.20 Hz, 2H), 4.25
(t, J = 5.36 Hz, 2H), 7.03-7.11 (m, 2H), 7.26-7.29 (m, 2H), 7.65 (br s, 1H), [M+Na+] = 296.67.
4.2.5. N-[(N-4-Chlorophenyl)sulfamoyl]perhydro-1,3-oxazin-2-one 7e. According to the typical
operating procedure (4.2) using the 1,3-chloropropanol as halogeno-alcohol, 7e was obtained in 65.13%
yield as white solid after column chromatography (eluent: CH2Cl2/MeOH = 95:5) and recrystallization
from CH2Cl2/n-hexane. Mp 173-175 °C; Rf: 0.60 (CH2Cl2/MeOH = 95:5); IR (KBr, cm-1): 3291 (NH),
1702 (C=O), 1272, 1161 (SO2); 1H NMR (300 MHz, CDCl3) 1.92 (q, 2H), 3.62 (t, J = 6.20 Hz, 2H), 4.26
(t, J = 5.36 Hz, 2H), 7.23-7.27 (m, 2H), 7.40-7.43 (m, 2H), 7.82 (br s, 1H), [M+Na+] = 313.52.
4.2.6. N-[(N-4-Nitrophenyl)sulfamoyl]perhydro-1,3-oxazin-2-one 7f. According to the typical
operating procedure (4.2) using the 1,3-chloropropanol as halogeno-alcohol, 7f was obtained in 69.22%

HETEROCYCLES, Vol. 83, No. 5, 2011
1053
yield as light yellow solid after column chromatography (eluent: CH3Cl/MeOH = 95:5) and
recrystallization from CH3Cl/n-hexane. Mp 186-188 °C; Rf: 0.48 (CH2Cl2/MeOH = 95:5); IR (KBr, cm-1):
1
3165 (NH), 1693 (C=O), 1387, 1227 (SO2); H NMR (300 MHz, DMSO-d6) 1.99 (q, 2H), 3.78 (t, J =
6.41 Hz, 2H), 4,30 (t, J = 5.35 Hz, 2H), 7.83-7.88 (m, 2H), 8.17-8.20 (m, 2H); 7.49 (br s, 1H), [M+Na+]
= 323.56.
4.3. Preparation of bacterial culture
Test clinical strains were S. aureus, E. coli and P. aeruginosa. three to five similar colony of each strain
was transferred into 3 ml of nutrient broth in a 22 ml test tube, then a suspensions in physiologic water
was prepared. Test strains were spread on solid nutrient agar surface by using sterile ekùvyon rod. The
growth obtained was diluted 1:10 so as to give an approximate concentration of 106-108 CFU/mL (0.5
McFarland standard) in conformity with the recommendations of the Clinical and Laboratory Standards
institute (CLSI, 2008). S. aureus ATCC 25923, E. coli 25922 and P.aeruginosa 27853 references strains
were used as control strains in order to monitor the antibacterial test.
4.4. Disc diffusion method (first screening)
The compounds 7a-7f were dissolved in dimethyl sulfoxyde (DMSO) (Merck) and then their antibacterial
effect were tested using selected concentration. Petri dishes (measuring 90 mm each side) containing
20ml Muller-Hinton agar (DIFCO Laboratories, IPP, France) were prepared as described above and then
dried at 35 °C for about 30 min in an incubator. At the same time, absorbent paper discs (6 mm) were
placed on the agar surface and then appropriate concentration of the compounds in DMSO were applied
onto the disks, and 300 µmol/L final concentrations were obtained for each disc. Sulfisoxazole ST (300
µmol/L) antibiotic disks were also used for all test microorganisms as positive control for evaluating the
data. The plates were incubated at 35 °C for 24 h. After that, the diameter of inhibition zone was
measured in millimeters by compass (mm). The size of inhibition zone was categorized into three classes:
<10: weak activity; >10: moderate activity; >16: Significant activity. In order to clarify any participating
role of DMSO in the bacterial screening, separate studies were carried out with the solutions alone of
DMSO and they showed no activity against all bacterial strains. All tests were repeated three times to
minimize test error.
4.5. Minimum inhibitory concentration (MIC)
Compounds containing significant antibacterial activity (>16 mm) were selected for minimum inhibitory
concentration (MIC) studies. The minimum inhibitory concentration was determined using the broth
microdilution method.43 The MIC determination of the tested compounds was investigated in comparison
with Sulfisoxazole. Double dilutions of the test compounds and reference drugs were prepared in Muller-
Hinton agar. 10 mg of each test compound were dissolved in 1 mL of dimethyl sulfoxide (DMSO)

1054
HETEROCYCLES, Vol. 83, No. 5, 2011
separately to prepare stock solution. Further, progressive dilutions with melted Mueller–Hinton agar were
performed to obtain the required concentrations of 500, 250, 125, 62.5, 31.25,16, 8, 4, 2,1 µg/mL. The
Petri dishes were inoculated with 1–5 x 104 colonies forming units (cfu/mL) and incubated at 37 °C for 18
h. The minimum inhibitory concentration (MIC) was the lowest concentration of the tested compounds
that yield no visible growth on the plate was recorded in Table 6. To ensure that the solvent had no effect
on the bacterial growth, a control was performed with the test medium supplemented with DMSO at the
same dilutions as used in the experiments.
SUPPLEMENTARY MATERIAL
Crystallographic data for the structural analysis of 7d have been deposited with the Cambridge
Crystallographic Data Centre (CCDC-N° 790885). Copies may be obtained free of charge on application
to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; by quoting the publication citation and the deposit
numbers. [Fax: (+44) 1223-336-033; E-mail: deposit@ccdc.cam.ac.uk, http://www.ccdc.cam.ac.uk]
This Work was supported by the (La Direction Générale de la Recherche Scientifique et de
Développement technologique (DGRS-DT), Ministère d’enseignement supérieure et de la recherche
scientifique (MESRS)-Algérie) through a research project (E2401/51/06).
REFERENCES
1. S. K. Fridkin, H. A. Hill, N. V. Volkova, J. R. Edwards, R. M. Lawton, R. P. Gaynes, and J. E.
McGrowan, J. Emerg. Infect. Dis., 2002, 8, 697.
2. F. M. Walsh and S. G. Amyes, Curr. Opin. Microbiol., 2004, 7, 439.
3. K. Motoshima, Y. Hiwasa, M. Yoshikawa, K. Fujimoto, A. Tai, H. Kakuta, and K. Sasaki, Chem.
Med. Chem., 2007, 2, 1527; N. Selvakumar, B. Y. Reddy, G. S. Kumar, M. K. Khera, D. Srinivas, M.
S. Kumar, J. Das, J. Iqbal, J. Trehan, and S. Trehan, Bioorg. Med. Chem. Lett., 2006, 16, 4416.
4. S. Brickner, J. Curr. Pharm. Des., 1996, 2, 175.
5. D. J. Diekema and R. N. Jones, Lancet, 2001, 358, 1975.
6. A. R. Renslo, G. W. Luehr, and M. F. Gordeev, Bioorg. Med. Chem. Lett., 2006, 14, 4227.
7. M. Bozdogan and P. C. Appelbaum, Int. J. Antimicrob. Agents, 2004, 23, 113.
8. M. R. Barbachyn and C. W. Ford, Angew. Chem. Int. Ed., 2003, 42, 2010.
9. D. K. Hutchinson, Curr.Top. Med. Chem., 2003, 3, 1021.
10. P. A. Masters, T. A. O’Bryan, J. Zurlo, D. Q. Miller, and N. Joshi, Arch. Intern. Med., 2003, 163, 402.
11. E. K. Kremer, G. Facchin, E. Estevez, P. Albores, E. J. Baran, J. Ellena, and M. H. Torre, J. Inorg.

HETEROCYCLES, Vol. 83, No. 5, 2011
1055
Biochem., 2006, 100, 1167.
12. G. E. de Kloe, D. Bailey, R. L. Iwan, and J. P. Esch, Drug Discovery Today, 2009, 14, 630; G.
Chessari and A. J. Woodhead, Drug Discovery Today, 2009, 14, 668.
13. G. Wang, J. R. Ella-Menye, and V. Sharma, Bioorg. Med. Chem. Lett., 2006, 16, 2177.
14. K. Yamana, N. Suzuki, A. Takahama, and S. Ine, Jpn. Kokai Tokkyo Koho, JP 179572. 2002 [Chem.
Abstr., 2002, 137, 57555].
15. F. Jin and P. N. Confalone, PCT Int. Appl. (119 pp) WO 2000/0000481. 2000 [Chem. Abstr., 2000,
132, 78560].
16. K. Namba, Xi. Zheng, K. Motoshima, H. Kobayashi, A. Tai, E. Takahashi, K. Sasaki, K. Okamoto,
and H. Kakuta, Bioorg. Med. Chem., 2008, 16, 6131.
17. D. R. Artis, J. Lin, C. Zhang, W. Wang, U. Mehra, M. Perreault, D. Erbe, H. I. Krupka, B. P.
England, J. Arnold, A. N. Plotnikov, A. Marimuthu, H. Nguyen, S. Will, M. Signaevsky, J. Kral, J.
Cantwell, C. Settachatgull, D. S. Yan, D. Fong, A. Oh, S. Shi, P. Womack, B. Powell, G. Habets, B.
L. West, K. Y. J. Zhang, M. V. Milburn, G. P. Vlasuk, K. P. Hirth, K. Nolop, G. Bollag, P. N.
Ibrahim, and J. F. Tobin, Proc. Natl. Sci. U.S.A., 2009, 106, 262.
18. M. Basanagouda, K. Shivashankar, M. V. Kulkarni, V. P. Rasal, H. Patel, S. S. Mutha, and A. A.
Mohite, Eur. J. Med. Chem., 2010, 45, 1151.
19. M. Nessaib, M. Abdaoui, A. G. Djahoudi, M. Kadri, and J.-Y. Winum, Recent Patents on Anti-
Infective Drug Discovery, 2007, 2, 131.
20. C. Yingjie, Y. Yushe, C. Kaixiane, J. Ruyun, and Z. Shuhua, Bioorg. Med. Chem. Lett., 2003, 13,
2311.
21. S. J. Kim, M. Jung, K. Yoo, J. Cho, and C. Oh, Bioorg. Med. Chem. Lett., 2008, 18, 5815.
22. H. Jeon, N. Jo, J. Cho, and C. H. Oh, Eur. J. Med. Chem., 2007, 42, 358.
23. G. Dewynter, M. Abdaoui, Z. Regainia, and J.-L. Montero, Tetrahedron, 1996, 52, 14217.
24. M. Abdaoui, G. Dewynter, and J. L. Montero, Tetrahedron. Lett., 1996, 32, 5695.
25. A. Borghese, L. Antoine, J. P. Van Hoeck, A. Mockel, and A. Merschaert, Org. Process Res. Devel.,
2006, 10, 770.
26. M. Kadri, R. Djemil, M. Abdaoui, J-Y. Winum, F. Coutrot, and J. L. Montero, Bioorg. Med. Chem,
Lett., 2005, 15, 889.
27. J.-L. Montero, G. Dewynter, B. Agoh, B. Dclaunay, and J. L. Imbach, Tetrahedron Lett., 1983, 24,
3091.
28. B. Agoh, G. Dewynter, J. L. Montero, A. Leydet, and J. L. Imbach, Bull. Soc. Chim. Fr., 1987, 5, 867.
29. Oxford Diffraction (2008) CrysAlis CCD and Crys Alis RED. Oxford Diffraction Ltd., Abingdon,
Oxfordshire, England.

1056
HETEROCYCLES, Vol. 83, No. 5, 2011
30. A. Altomare, M. C. Burla, M. Camalli, G. L. Cascarano, C. Giacovazzo, A. Guagliardi, A. G. G.
Moliterni, G. Polidori, and R. Spagna, J. Appl. Cryst., 1999, 32, 115.
31. G. M. Sheldrick, Acta Cryst. A., 2008, 64, 112.
32. L. J. Farrugia, J. Appl. Cryst., 1997, 30, 565.
33. S. Dokhane, N. Benali-Cherif, and M. Abdaoui, Acta Cryst. E., 2002, 58, 570.
34. A. Seridi, H. Akkari, J.-Y. Winum, P. Bénard-Rocherullé, and M. Abdaoui, Acta Cryst. E., 2009, 65,
2543.
35. M. C. Etter, J. C. MacDonald, and J. Bernstein, Acta. Cryst. B., 1990, 46, 256.
36. J. Bernstein, R. E. Davis, L. Shimoni, and N. L Chang, Angew. Chem., Int. Ed. Engl., 1995, 34, 1555.
37. K. Brandenburg and M. Berndt, 2001. DIAMOND. Crystal Impact GbR, Bonn, Germany.
38. A. Giacometti, O. Cirioni, W. Kamysz, G. D’Amato, C. Silvestri, M. S. Del Prete, A. Licci, A. Riva,
J. Lukasiak, and G. Scalise, Antimicrob. Agents Chemother., 2005, 49, 1249.
39. J. A. Swenson, J. Spargo, F. C. Tenover, and M. J. J. Ferraro, Clin. Microbiol, 2001, 39, 3781.
40. K. Isik and F. Ozdemir-Kocak, Microbiological Research, 2009, 164, 49.
41. M. Fenech, C. Aitken, and J. Rinaldi, Carcinogenesis, 1998, 19, 1163.
42. W. Armstrong, S. Meshnick, and P. Kazanjian, Microbes Infect, 2000, 2, 61.
43. E. W. Koneman, S. D. Allen, W. M. Janda, P. C. Schreckenberger, and W. C. Winn, Jr., Color Atlas
and Textbook of Diagnostic Microbiology, fifth ed. Lippincott- Raven Publishers, Philadelphia, USA,
1997, pp. 785–856.